Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
ImmunityBio, Inc. | Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | Common Stock | 32.6M | $164M | $5.02 | Sep 11, 2023 | Indirect |
ImmunityBio, Inc. | Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | Common Stock | 29.5M | $148M | $5.02 | Sep 11, 2023 | Direct |
NantHealth, Inc. | Chief Executive Officer, Director, 10%+ Owner | Common Stock | 15.9M | $31.2M | $1.96 | Aug 28, 2023 | Indirect |
ImmunityBio, Inc. | Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | Restricted Stock Units | 343K | $1.39M | $4.04 | Feb 22, 2024 | Direct |
ImmunityBio, Inc. | Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | Stock Option (right to buy) | 1.19M | Feb 22, 2024 | Direct | ||
ImmunityBio, Inc. | Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | Amended and Restated Convertible Promissory Note | $0 | Sep 11, 2023 | Indirect | ||
ImmunityBio, Inc. | Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | Amended and Restated Promissory Note | $380M | Dec 29, 2023 | Indirect | ||
ImmunityBio, Inc. | Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | Convertible Promissory Note | $30M | Dec 29, 2023 | Indirect | ||
ImmunityBio, Inc. | Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | Second Amended and Restated Convertible Promissory Note | $0 | Sep 11, 2023 | Indirect |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
IBRX | ImmunityBio, Inc. | Feb 22, 2024 | 2 | $0 | 4 | Feb 26, 2024 | Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner |
IBRX | ImmunityBio, Inc. | Dec 29, 2023 | 2 | $410M | 4 | Jan 3, 2024 | Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner |
IBRX | ImmunityBio, Inc. | Sep 11, 2023 | 9 | $200M | 4 | Sep 13, 2023 | Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner |
NHIQ | NantHealth, Inc. | Aug 28, 2023 | 2 | $16M | 4 | Aug 30, 2023 | Chief Executive Officer, Director, 10%+ Owner |
IBRX | ImmunityBio, Inc. | May 12, 2023 | 1 | $30.5M | 4 | May 16, 2023 | Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner |
IBRX | ImmunityBio, Inc. | Dec 12, 2022 | 2 | -$5 | 4 | Dec 14, 2022 | Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner |
IBRX | ImmunityBio, Inc. | Aug 31, 2022 | 6 | $315M | 4 | Nov 8, 2022 | Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner |
IBRX | ImmunityBio, Inc. | Mar 23, 2022 | 2 | $0 | 4 | Mar 25, 2022 | Executive Chairman, Director, 10%+ Owner |
NHIQ | NantHealth, Inc. | Sep 9, 2021 | 1 | $0 | 4 | Sep 13, 2021 | Chairman and CEO, Director, 10%+ Owner |
IBRX | ImmunityBio, Inc. | Jun 10, 2021 | 1 | $0 | 4 | Jun 14, 2021 | Executive Chairman, Director, 10%+ Owner |